To hear about similar clinical trials, please enter your email below
Trial Title:
Prognostic Value of Some Biochemical Markers in Breast Cancer
NCT ID:
NCT05699577
Condition:
Breast Cancer Female
Conditions: Official terms:
Breast Neoplasms
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
serum sample for ELIZA
Description:
ELIZA for Ca15-3 and interferon gamma
Arm group label:
metastatic breast cancer
Arm group label:
non metastatic breast cancer
Summary:
breast cancer is the most common type of cancer in women and first cause of cancer death
among them. in Egypt it constitutes 33% of female cancer cases and more than22000 new
cases diagnosed each year. there are many prognostic factors for breast cancer as Tumer
size, axillary lymph node status, hormonal receptor status, and tumer markers as Ca15-3
and interferon gamma.
Criteria for eligibility:
Study pop:
female patients with breast cancer
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- female patients aged more than or equal 18 year diagnosed with breast cancer
- metastatic and non-metastatic cancer premenopausal and postmenopausal female
positive and negative hormonal receptors and HER2 receptor taking any systemic
treatment taking radiotherapy or not
Exclusion Criteria:
- female patients less than 18 years patients having comorbid disease. patients with
double malignancy
Gender:
Female
Gender based:
Yes
Minimum age:
18 Years
Maximum age:
60 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Sohag University Hospital
Address:
City:
Sohag
Country:
Egypt
Contact:
Last name:
magdy m amin, professor
Start date:
February 2023
Completion date:
December 2023
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05699577
